Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature

• Published in: Journal of oncology pharmacy practice Vol. 24; no. 7; p. 544
• Main Authors: Titus-Rains, Krystal S, Brown, Jamie N, Hammond, Julia M
• Format: Journal Article
• Language: English
• Published: England 01.10.2018
• Subjects: Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Lymphoma, Mantle-Cell - drug therapy; Male; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Tumor Lysis Syndrome - etiology; ibrutinib; Bruton tyrosine kinase inhibitor; medication safety; tumor lysis syndrome

Background Tumor lysis syndrome results when intracellular contents are released during cell lysis. Ibrutinib, a Bruton tyrosine kinase inhibitor, is used for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström's macroglobulinemia, mantle cell lymphoma, and ma...